Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
19
datasets available to search
ShareScore release 0.9.0
Dataset results
19 results for “Myeloma Microenvironment”
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
<p> </p> <table> <tbody> <tr> <td>rowID</td> <td>filename</td> <td>date</td> <td>batch</td> <td>group</td> <td>ID</td> </tr> <tr> <td>1</td> <td>20200121_bm003696_RMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>RMM</td> <td>bm003696</td> </tr> <tr> <td>2</td> <td>20200121_bm054122_DRMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>DRMM</td> <td>bm054122</td> </tr> <tr> <td>3</td> <td>20200121_bm054496_RMM_tx_02.FCS</td> <td>20200121</td> <td>1</td> <td>RMM</td> <td>bm054496</td> </tr> <tr> <td>4</td> <td>20200121_bm059645_NDMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>NDMM</td> <td>bm059645</td> </tr> <tr> <td>5</td> <td>20200121_bm060791_NDMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>NDMM</td> <td>bm060791</td> </tr> <tr> <td>6</td> <td>20200121_bm064862_DRMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>DRMM</td> <td>bm064862</td> </tr> <tr> <td>7</td> <td>20200121_REF2_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>8</td> <td>20200124_BM038232_RMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>RMM</td> <td>BM038232</td> </tr> <tr> <td>9</td> <td>20200124_BM051757_NDMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>NDMM</td> <td>BM051757</td> </tr> <tr> <td>10</td> <td>20200124_BM052673_DRMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>DRMM</td> <td>BM052673</td> </tr> <tr> <td>11</td> <td>20200124_BM053393_NDMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>NDMM</td> <td>BM053393</td> </tr> <tr> <td>12</td> <td>20200124_BM053570_RMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>RMM</td> <td>BM053570</td> </tr> <tr> <td>13</td> <td>20200124_BM059775_DRMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>DRMM</td> <td>BM059775</td> </tr> <tr> <td>14</td> <td>20200124_REF2_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>15</td> <td>20200128_3-1-BM060915-DRMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>DRMM</td> <td>BM060915</td> </tr> <tr> <td>16</td> <td>20200128_3-2-BM064896-DRMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>DRMM</td> <td>BM064896</td> </tr> <tr> <td>17</td> <td>20200128_3-3-BM059424-NDMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>NDMM</td> <td>BM059424</td> </tr> <tr> <td>18</td> <td>20200128_3-4-BM059429-NDMM_TX_02.FCS</td> <td>20200128</td> <td>3</td> <td>NDMM</td> <td>BM059429</td> </tr> <tr> <td>19</td> <td>20200128_3-5-BM043778-RMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>RMM</td> <td>BM043778</td> </tr> <tr> <td>20</td> <td>20200128_3-6-BM008007-RMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>RMM</td> <td>BM008007</td> </tr> <tr> <td>21</td> <td>20200129_3-7-ref2_tax_01.FCS</td> <td>20200129</td> <td>3</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>22</td> <td>20200204_5-1_BM054866-DRMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>DRMM</td> <td>BM054866</td> </tr> <tr> <td>23</td> <td>20200204_5-2_BM065069-DRMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>DRMM</td> <td>BM065069</td> </tr> <tr> <td>24</td> <td>20200204_5-3_BM035491-NDMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>NDMM</td> <td>BM035491</td> </tr> <tr> <td>25</td> <td>20200204_5-4_BM0333015-NDMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>NDMM</td> <td>BM0333015</td> </tr> <tr> <td>26</td> <td>20200204_5-5_BM0052990-RMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM0052990</td> </tr> <tr> <td>27</td> <td>20200204_5-5_BM0052990-RMM-Tx_02.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM0052990</td> </tr> <tr> <td>28</td> <td>20200204_5-5_BM052990-RMM-Tx_02.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM052990</td> </tr> <tr> <td>29</td> <td>20200204_5-6_BM052692-RMM-Tx_02.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM052692</td> </tr> <tr> <td>30</td> <td>20200204_5-7 -Ref2-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>31</td> <td>20200207_6-1_BM063515_DRMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>DRMM</td> <td>BM063515</td> </tr> <tr> <td>32</td> <td>20200207_6-2_BM054226_DRMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>DRMM</td> <td>BM054226</td> </tr> <tr> <td>33</td> <td>20200207_6-3_BM008346_NDMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>NDMM</td> <td>BM008346</td> </tr> <tr> <td>34</td> <td>20200207_6-4_BM008718_NDMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>NDMM</td> <td>BM008718</td> </tr> <tr> <td>35</td> <td>20200207_6-5_BM052764_RMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>RMM</td> <td>BM052764</td> </tr> <tr> <td>36</td> <td>20200207_6-6_Ref2_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>37</td> <td>20200211_7-1_BM061912_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM061912</td> </tr> <tr> <td>38</td> <td>20200211_7-2_BM059328_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM059328</td> </tr> <tr> <td>39</td> <td>20200211_7-3_BM065082_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM065082</td> </tr> <tr> <td>40</td> <td>20200211_7-4_BM008353_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM008353</td> </tr> <tr> <td>41</td> <td>20200211_Ref2_Tax_02.FCS</td> <td>20200211</td> <td>7</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>42</td> <td>20200214_4-1_BM062618_DRMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>DRMM</td> <td>BM062618</td> </tr> <tr> <td>43</td> <td>20200214_4-2_BM062255_DRMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>DRMM</td> <td>BM062255</td> </tr> <tr> <td>44</td> <td>20200214_4-3_BM032596_NDMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>NDMM</td> <td>BM032596</td> </tr> <tr> <td>45</td> <td>20200214_4-4_BM047845_NDMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>NDMM</td> <td>BM047845</td> </tr> <tr> <td>46</td> <td>20200214_4-5_BM042666_RMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>RMM</td> <td>BM042666</td> </tr> <tr> <td>47</td> <td>20200214_4-6_Ref2_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>REF</td> <td>REF2</td> </tr> </tbody> </table> <p> </p> <p>*files with row ID #26 and #27 need to be concatenated since they represent the same sample acquired over 2 files</p>
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
<p>BCMA-targeted CAR-T therapy has shown potent treatment outcomes in treating multiple myeloma (MM), a disease characterized by malignant bone marrow (BM) plasma cells. However, the remodeling of MM microenvironment after CAR-T therapy remains poorly understood. Here, we report the reconstitution of MM microenvironment by obtaining single-cell transcriptomes for paired BM specimens (n = 14) from 7 MM patients before (<em>i.e.</em>, baseline, ''day −4'') and after (<em>i.e.</em>, ''day 28'') post-lymphodepleted BCMA CAR-T therapy. Our analysis revealed heterogeneity in driver gene expression among MM cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8<sup>+</sup> effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells (Tregs), enhanced CD8<sup>+</sup> effector T cell cytotoxic activity, and elevated type 1 conventional dendritic cell (cDC1) antigen presentation ability. DC re-clustering inferred intramedullary-originated cDC3s with extramedullary migration. Cell-cell communication network analysis indicated BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway-mediated immunosuppression and activates MIF pathway-mediated anti-MM immunity. Our study sheds light on MM microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.</p>
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
Open the record for dataset details and reuse information.
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
ClinicalTrials.gov study NCT02112045. IPD Sharing: NO. Countries: 1. Publications: 0.
Single cell Transcriptomic analysis of CD8+ T cells treated with anti-CD137 agonists within VK12653 Multiple Myeloma bone marrow microenvironment .
GEO Series GSE205702. Mus musculus. 10 samples. Type: Expression profiling by high throughput sequencing.
Spatial transcriptomics unveils novel potential disease mechanisms associated with the microenvironment in Multiple Myeloma
GEO Series GSE269875. Homo sapiens; Mus musculus. 15 samples. Type: Other.
Gene expression analysis of the bone marrow microenvironment reveals distinct immunotypes in smoldering multiple myeloma associated to progression to symptomatic disease
GEO Series GSE186537. Homo sapiens. 72 samples. Type: Expression profiling by array.
Transcriptomic analysis of Multiple Myeloma bone marrow microenvironment
GEO Series GSE104171. Homo sapiens. 74 samples. Type: Expression profiling by high throughput sequencing.
A single-cell atlas of the mouse Multiple Myeloma immune microenvironment during tumor progression
GEO Series GSE271306. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
<p>This repository contains R Seurat objects associated with our study titled "<strong>A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma</strong>". </p> <p>This repository contains two Seurat objects stored in .rds files containing processed single-cell RNA sequencing data from the original ‘Discovery’ cohort of the MMRF Immune Atlas study, along with an additional ‘Discovery + Validation’ cohort, as described in the original publication. These .rds files contain Seurat v4 objects with basic cell type annotation and qc metadata. Specific file contents will be detailed below.</p> <div> <p>A copy of the ‘Cell Annotation Dictionary’ is also included, which contains additional details on the individual annotated clusters in the Immune Atlas dataset.</p> <p>Information on how to request additional metadata about these samples and accessing the original fastq files will be detailed at the end of this description</p> </div>
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)
ClinicalTrials.gov study NCT06154317. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_3
GEO Series GSE136398. Homo sapiens. 131 samples. Type: Expression profiling by array.
Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment
GEO Series GSE136400. Homo sapiens. 1424 samples. Type: Expression profiling by array.
Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_1
GEO Series GSE136324. Homo sapiens. 867 samples. Type: Expression profiling by array.
Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_2
GEO Series GSE136337. Homo sapiens. 426 samples. Type: Expression profiling by array.
Lenalidomide and Pomalidomide inhibit Multiple Myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules.
GEO Series GSE37302. Homo sapiens. 9 samples. Type: Expression profiling by array.
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
GEO Series GSE124310. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment
GEO Series GSE99293. Homo sapiens. 3 samples. Type: Expression profiling by high throughput sequencing.
Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
GEO Series GSE271915. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.